Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1484383
This article is part of the Research Topic Challenges and Advances in Carcinomatous Meningitis Treatment View all 3 articles

A rare case of vision loss caused by leptomeningeal metastasis of lung adenocarcinoma: a case report and literature review

Provisionally accepted
Zhihua LI Zhihua LI 1*Jian Chu Jian Chu 2Wennan Shen Wennan Shen 1*Junnan Chen Junnan Chen 1*Yuemei Dong Yuemei Dong 1*Manze Zhang Manze Zhang 1Nan Zhao Nan Zhao 1Wei Zhao Wei Zhao 1Haoran Zha Haoran Zha 1Yalin Han Yalin Han 1Ning Wang Ning Wang 1Zhaoxia Li Zhaoxia Li 1*
  • 1 Department of Oncology, PLA Rocket Force Characteristic Medical Center, Beijing, China
  • 2 Department of Thoracic Surgery, PLA Rocket Force Characteristic Medical Center, Beijing, China

The final, formatted version of the article will be published soon.

    Leptomeningeal metastasis (LM) is a fatal complication with increasing incidence in patients with non-small cell lung cancer. Herein, we present the case of a patient who presented with complete vision loss due to LM and achieved a survival benefit from treatment with trametinib. The treatment was prescribed based on the detection of a BRAF non-V600E mutation in the cerebrospinal fluid (CSF). We reviewed the literature and evaluated survival benefits in patients with LM harboring BRAF non-V600E mutations treated with CSF chemotherapy and mitogen-activated extracellular signal-regulated kinase inhibitors.

    Keywords: Leptomeningeal metastasis, BRAF non-V600E mutation, NSCLC, trametinib, Vision Loss, case report

    Received: 21 Aug 2024; Accepted: 13 Jan 2025.

    Copyright: © 2025 LI, Chu, Shen, Chen, Dong, Zhang, Zhao, Zhao, Zha, Han, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Zhihua LI, Department of Oncology, PLA Rocket Force Characteristic Medical Center, Beijing, China
    Wennan Shen, Department of Oncology, PLA Rocket Force Characteristic Medical Center, Beijing, China
    Junnan Chen, Department of Oncology, PLA Rocket Force Characteristic Medical Center, Beijing, China
    Yuemei Dong, Department of Oncology, PLA Rocket Force Characteristic Medical Center, Beijing, China
    Zhaoxia Li, Department of Oncology, PLA Rocket Force Characteristic Medical Center, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.